Cited by 598Mitochondrial Function and PathologyAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record.

Cytochrome oxidase deficiency in Alzheimer’s disease

Parker, William Davis, Filley, Christopher M., Parks, Janice K.·1990·Neurology

DOI 10.1212/wnl.40.8.1302

Open this paper in CoChat — free account

Abstract

We assayed cytochrome oxidase and other electron transport chain activities in platelet mitochondria isolated from patients with Alzheimer's disease (AD). Five of 6 patients had striking reductions of platelet cytochrome oxidase activity (patient mean, 83.72 +/- 82.99 nmol/min/mg; control mean, 167.14 +/- 36.21 nmol/min/mg; n = 8). Other electron transport chain catalytic activities were not significantly different than control values. AD may be a systemic illness, a primary defect in cytochrome oxidase may be pathogenically important in its production, and the mitochondrial genes encoding cytochrome oxidase subunits may be important in producing the defect.

Integrity signals

Registry

Crossref · 10.1212/wnl.40.8.1302

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,434
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Mitochondrial Genetics: A Paradigm for Aging and Degenerative Diseases?
Wallace, D. C. (1992) · Science · doi:10.1126/science.1533953 · Cited by 1,262
Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease
Mecocci, P., MacGarvey, U., & Beal, M. F. (1994) · Annals of Neurology · doi:10.1002/ana.410360510 · Cited by 1,037
Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease
Reddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age
Corral-Debrinski, M., Horton, T., Lott, M. T., Shoffner, J. M., Flint Beal, M., & Wallace, D. C. (1992) · Nature Genetics · doi:10.1038/ng1292-324 · Cited by 890
Mitochondria and Mitochondrial Cascades in Alzheimer’s disease
Swerdlow, R. H. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170585 · Cited by 850
“cytochrome oxidase (COX) activity [21].”
Background
Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction
Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G., & Anandatheerthavarada, H. K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1469-06.2006 · Cited by 792
“Altered mitochondrial fluidity and the activity of mitochondrial cytochrome c oxidase, which is the terminal oxidase in the respiratory chain, have been reported to be low in the AD brains (Parker, 1991; Sims, 1996; Maurer et al., 2000).”
Background
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains
Walker, J. E. (1992) · Quarterly Reviews of Biophysics · doi:10.1017/s003358350000425x · Cited by 777
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758
Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death
Bains, J. S., & Shaw, C. A. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00045-3 · Cited by 718
Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer’s disease Neurons
Rajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 730
The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae
Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P. F., Alafuzoff, I., Leinonen, V., Ito, A., Winblad, B., Glaser, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806192105 · Cited by 693
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Origin and functional consequences of the complex I defect in Parkinson's disease
Swerdlow, R. H., Parks, J. K., Miller, S. W., Davis, R. E., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P., & Parker, W. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400417 · Cited by 638
Self-citation
Mitochondrial disease
Schapira, A. H. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68970-8 · Cited by 617
Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
Beal, M. F., Hyman, B. T., & Koroshetz, W. J. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90117-5 · Cited by 574
Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells
Anandatheerthavarada, H. K., Biswas, G., Robin, M.-A., & Avadhani, N. G. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207030 · Cited by 571
“…$8.00 The Journal of Cell Biology, Volume 161, Number 1, April 14, 2003 41–54 http://www.jcb.org/cgi/doi/10.1083/jcb.200207030 JCB Article 41 Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells”
BackgroundInfluential
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562
“Reduced AD subject cytochrome oxidase activity was first reported in 1990 [20].”
Background
Brain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537
Estrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
“…brain tissue (Cottrell et al., 2001; Kish et al., 1992; Maurer et al., 2000; Mutisya et al., 1994; Parker et al., 1994b) as well as platelets (Bosetti et al., 2002; Cardoso et al., 2004; Parker et al., 1990, 1994a; Valla et al., 2006a) and fibroblasts (Curti et al., 1997) from AD patients.”
Mitochondrial DNA sequence variation in human evolution and disease.
Wallace, D. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8739 · Cited by 525
Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases
Hashimoto, M., Rockenstein, E. M., Crews, L. A., & Masliah, E. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:21 · Cited by 508
Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View
Cenini, G., Lloret, A., & Cascella, R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2105607 · Cited by 521
“Studies performed in AD patients showed reduced cytochrome oxidase activity in platelets of AD subjects when compared to controls [74], and this mitochondrial defect was also demonstrated in the brain of AD patients [75].”
Background
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P. F., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
β‐Amyloid inhibits integrated mitochondrial respiration and key enzyme activities
Casley, C. S., Canevari, L., Land, J. M., Clark, J. B., & Sharpe, M. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00681.x · Cited by 485
“Platelets from AD patients show reduced cytochrome oxidase activity despite having no interaction with amyloid plaques (Parker et al. 1990).”
Background
A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients
Maurer, I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00112-3 · Cited by 475
Amyloid toxicity in Alzheimer’s disease
Reiss, A. B., Arain, H. A., Stecker, M. M., Siegart, N. M., & Kasselman, L. J. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0063 · Cited by 447
Mitochondrial dysfunction in Alzheimer's disease: role in pathogenesis and novel therapeutic opportunities
Perez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426
“These enzymes include (a) cytochrome c oxidase (COX; i.e., complex IV; Maurer, Zierz, & Möller, 2000; Mutisya, Bowling, & Beal, 1994; Parker et al., 1990), (b) pyruvate dehydrogenase complex (Gibson, Starkov, Blass, Rata, & Beal, 2010), and (c) the Krebs cycle α‐ ketoglutarate dehydrogenase complex (Gibson et al.”
Background
Brain Energy and Oxygen Metabolism: Emerging Role in Normal Function and Disease
Watts, M. E., Pocock, R., & Claudianos, C. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00216 · Cited by 438
Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., Shirendeb, U. P., Calkins, M. J., Reddy, A. P., Mao, P., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.011 · Cited by 394
Mitochondrial dysfunction in neurodegenerative disorders
Klemmensen, M. M., Borrowman, S. H., Pearce, C., Pyles, B., & Chandra, B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.002 · Cited by 396
An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
Cassarino, D. S., & Bennett, J. P. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00046-0 · Cited by 383
The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
“cytochrome oxidase activity (but not of other electron transport chain enzymes) in platelets of patients [27] and the same finding has been confirmed in an independent study detecting reduced ATP levels, increased reactive oxygen species, and decreased cytochrome oxidase activity (but normal cytochrome oxidase subunit…”
Background
Topical Review: Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Strokelike Episodes (MELAS): Current Concepts
Hirano, M., & Pavlakis, S. G. (1994) · Journal of Child Neurology · doi:10.1177/088307389400900102 · Cited by 365
Bioenergetic and oxidative stress in neurodegenerative diseases
Bowling, A. C., & Beal, M. F. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00055-b · Cited by 364
Are reactive oxygen species involved in Alzheimer's disease?
Benzi, G. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00066-n · Cited by 365
Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease.
Pappolla, M. A., Omar, R. A., Kim, K. S., & Robakis, N. K. R. K. (1992) · PubMed Central · Cited by 363
Amyloid precursor protein‐mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease
Reddy, P. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03530.x · Cited by 367
Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer’s disease
Bosetti, F. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00314-1 · Cited by 348
Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease
Manczak, M., & Reddy, P. H. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds360 · Cited by 348
Abnormalities of mitochondrial enzymes in Alzheimer disease
Gibson, G. E., Sheu, K.-F. R., & Blass, J. P. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050099 · Cited by 345
“Deficiency of COX activity in platelets has been reported (Parker et al., 1990) and disputed (VanZuylen et al., 1992).”
Background
RETRACTED: Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
Self-citation
Retracted
Oxidative stress in Alzheimer's disease
Chauhan, V. P. S., & Chauhan, A. (2006) · Pathophysiology · doi:10.1016/j.pathophys.2006.05.004 · Cited by 349
Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants
Cui, K., Luo, X., Xu, K., & Murthy, M. R. V. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.023 · Cited by 334
Cellular metabolic and autophagic pathways: Traffic control by redox signaling
Dodson, M. B., Darley-Usmar, V. M., & Zhang, J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.014 · Cited by 333
Mitochondria, calcium and cell death: A deadly triad in neurodegeneration
Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., & Rizzuto, R. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.02.021 · Cited by 335
Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer’s Disease
Hroudová, J., Singh, N., & Fišar, Z. (2014) · BioMed Research International · doi:10.1155/2014/175062 · Cited by 319
“Volume 2014, Article ID 175062, 9 pages http://dx.doi.org/10.1155/2014/175062 in neurodegenerative process might affect mitochondrial parameters and also ATP production, membrane potential, permeability transition pore (MPTP) activation, and calcium uptake.”
BackgroundInfluential
Amyloid‐Beta Interaction with Mitochondria
Pagani, L., & Eckert, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/925050 · Cited by 309
Brain aging, Alzheimer's disease, and mitochondria
Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306
“In addition to the brain, reduced COX activity is also seen in AD subject platelets and fibroblasts [127, 128].”
Background
The development of mitochondrial medicine.
Luft, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8731 · Cited by 303
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Beal, M. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_16 · Cited by 298
Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines
Trimmer, P. A., Swerdlow, R. H., Parks, J. K., Keeney, P. M., Bennett, J. P., Miller, S. W., Davis, R. E., & Parker, W. D. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7333 · Cited by 296
Self-citation
Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin
Rosales‐Corral, S., Acuña-Castroviejo, D., Coto‐Montes, A. M., Boga, J. A., Manchester, L. C., Fuentes‐Broto, L., Korkmaz, A., Ma, S., Tan, D. X., & Reiter, R. J. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00937.x · Cited by 299
“Likewise, AD as a primary defect in cytochrome oxidase was proposed years later [314].”
Background
Are mitochondria critical in the pathogenesis of Alzheimer's disease?
Reddy, P. H., & Beal, M. F. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.03.004 · Cited by 294
Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases
Gan, L., & Johnson, J. A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.011 · Cited by 288
Mitochondria and degenerative disorders
Orth, M., & Schapira, A. H. V. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1425 · Cited by 281
Cytochrome c oxidase is decreased in Alzheimer’s disease platelets
Cardoso, S. M., Proença, M. T., Santos, S., Santana, I., & Oliveira, C. R. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00033-2 · Cited by 281
“A previous study of AD platelet bioenergetics using crude homogenates failed to find a complex IV defect [33] while one study that assessed complex IV activity in purified mitochondrial fractions found an ∼50% defect [20].”
BackgroundResultInfluential
Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer’s Disease
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease
Atamna, H., & Frey, W. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.06.001 · Cited by 278
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 284
“Reduced activity of complex IV, also known as cytochrome c oxidase (COX), has been widely reported in platelets as well as within the brain, which supports the view of AD being a systemic disorder (Parker et al., 1990; Cardoso et al., 2004).”
Background
Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer’s Disease
Cai, Q., & Tammineni, P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160726 · Cited by 281
“AD brains [76–84].”
Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease
Reddy, P. H. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.042 · Cited by 266
Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases
Cai, Q., & Jeong, Y. Y. (2020) · Cells · doi:10.3390/cells9010150 · Cited by 270
Vitamin E and Alzheimer disease: the basis for additional clinical trials
Grundman, M. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.630s · Cited by 269
A Long Journey into Aging, Brain Aging, and Alzheimer’s Disease Following the Oxidative Stress Tracks
Mecocci, P., Boccardi, V., Cecchetti, R., Bastiani, P., Scamosci, M., Ruggiero, C., & Baroni, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170732 · Cited by 259
“The fact that some mitochondrial defects observed in AD patients are not brain-limited, as shown by lower enzymatic activity, such as cytochrome oxidase, in mitochondria from peripheral cells (platelets and fibroblasts), strongly support the concept that AD is a systemic disease [31, 32].”
Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease
Sheehan, J. P., Swerdlow, R. H., Miller, S. W., Davis, R. E., Parks, J. K., Parker, W. D., & Tuttle, J. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-12-04612.1997 · Cited by 249
Self-citation
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Amyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101020 · Cited by 264
“ly stages of AD, there is already a reduction in the number of mitochondria [280] and the activities of tricarboxylic acid cycle enzymes [281] and COX [282].”
Bioenergetics and glutamate excitotoxicity
Greene, J. G., & Greenamyre, J. T. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00006-8 · Cited by 250
Amyloid-β and Mitochondria in Aging and Alzheimer's Disease: Implications for Synaptic Damage and Cognitive Decline
Reddy, P. H., Mańczak, M., Mao, P., Calkins, M. J., Reddy, A. P., & Shirendeb, U. P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100504 · Cited by 247
“their platelets [78], in AD transgenic mice [34,37,38,”
Energy Hypometabolism in Posterior Cingulate Cortex of Alzheimer's Patients: Superficial Laminar Cytochrome Oxidase Associated with Disease Duration
Valla, J. E., Berndt, J. D., & Gonzalez-Lima, F. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04923.2001 · Cited by 241
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease
Holper, L., Ben‐Shachar, D., & Mann, J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0090-0 · Cited by 236
Mitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230
“Decreased levels of mitochondrial enzymes––including pyruvate dehydrogenase complex, a-ketoglutarate dehydrogenase complex, and cytochrome oxidase––have been reported (Parker et al. 1990; Gibson et al. 1998).”
Background
Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease
Mecocci, P. (2002) · Archives of Neurology · doi:10.1001/archneur.59.5.794 · Cited by 229
Is Alzheimer’s disease a systemic disease?
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.012 · Cited by 219
Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Reddy, P. H., & Reddy, T. P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745401 · Cited by 233
Gradual Alteration of Mitochondrial Structure and Function by β-Amyloids: Importance of Membrane Viscosity Changes, Energy Deprivation, Reactive Oxygen Species Production, and Cytochrome c Release
Aleardi, A. M., Benard, G., Augereau, O., Malgat, M., Talbot, J.-C., Mazat, J., Letellier, T., Dachary-Prigent, J., Solaini, G., & Rossignol, R. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-6631-3 · Cited by 227
Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine
Ben-Shachar, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01263.x · Cited by 232
Contributory mechanisms in the causation of neurodegenerative disorders
Lees, G. J. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90254-d · Cited by 223
Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer’s Disease Pathogenesis
Chakravorty, A., Jetto, C. T., & Manjithaya, R. R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00311 · Cited by 225
Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?
Macdonald, R., Barnes, K., Hastings, C., & Mortiboys, H. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170501 · Cited by 223
Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain
Mecocci, P., Beal, M. F., Cecchetti, R., Polidori, M. C., Cherubini, A., Chionne, F., Avellini, L., Romano, G., & Senin, U. (1997) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815160 · Cited by 215
Mitochondrial complex i subunits expression is altered in schizophrenia: a postmortem study
Karry, R., Klein, E., & Ben‐Shachar, D. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.012 · Cited by 209
The Alzheimer's disease mitochondrial cascade hypothesis: an update
Swerdlow, R. H., & Khan, S. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.01.011 · Cited by 206
“The AD CO Vmax activity reduction was first shown in platelets in 1990 and brain in 1992 (Parker et al., 1990; Kish et al., 1992).”
Background
Mitochondrial alterations Alzheimer's disease
Baloyannis, S. J., Costa, V., & Michmizos, D. (2004) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750401900205 · Cited by 206
Functional mitochondria are required for amyloid β‐mediated neurotoxicity
Cardoso, S. M., Santos, S., Swerdlow, R. H., & Oliveira, C. R. (2001) · The FASEB Journal · doi:10.1096/fj.00-0561fje · Cited by 203
“Other data suggest that bioenergetic failure resulting from depressed cytochrome c oxidase activity and reactive oxygen species (ROS) overproduction could contribute to neuronal death in AD (6, 7, 8).”
Background
Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease
Swerdlow, R. H. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4149 · Cited by 206
“Apolipoprotein E4 (1-272) fragment is associ-”
Background
Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease.
Chandrasekaran, K., Giordano, T., Brady, D., Stoll, J., Martin, L. J., & Rapoport, S. (1994) · Brain Research. Molecular Brain Research · doi:10.1016/0169-328x(94)90147-3 · Cited by 221
Redox Reactions of Copper Complexes Formed with Different β-Amyloid Peptides and Their Neuropathalogical Relevance
Jiang, D., Men, L., Wang, J., Zhang, Y., Chickenyen, S., Wang, Y., & Zhou, F. (2007) · Biochemistry · doi:10.1021/bi700508n · Cited by 204
Emerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 206
“75) are also significant contributors to the pathogenesis of AD.”
Background
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 213
“A similar finding was made in AD brains in 1992 (Parker et al., 1990a; Kish et al., 1992).”
BackgroundResult
Potential Therapeutic Benefits of Strategies Directed to Mitochondria
Camara, A. K. S., Lesnefsky, E. J., & Stowe, D. F. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2788 · Cited by 199
“It is noteworthy that at an early stage of AD there is already a reduced number of mitochondria (247, 257), brain glucose metabolism is decreased (247, 287), and the activities of TCA cycle enzymes (79, 520) and cytochrome c oxidase are reduced (97, 247, 441) while there is enhanced cytochrome c release (177, 296), mP…”
Background
Mitochondrial Amyloid-β Levels are Associated with the Extent of Mitochondrial Dysfunction in Different Brain Regions and the Degree of Cognitive Impairment in Alzheimer's Transgenic Mice
Dragicevic, N., Mamcarz, M. B., Zhu, Y., Buzzeo, R. W., Tan, J., Arendash, G. W., & Bradshaw, P. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100342 · Cited by 197
Mitochondrial genes are altered in blood early in Alzheimer's disease
Lunnon, K., Keohane, A., Pidsley, R., Newhouse, S., Riddoch-Contreras, J., Thubron, E. B., Devall, M., Soininen, H., Kłoszewska, I., Mecocci, P., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.029 · Cited by 190
“…of oxidative damage in AD brain appear to be mirrored in the periphery including in platelets (Bosetti et al., 2002; Cardoso et al., 2004; Parker et al., 1990; Valla et al., 2006) and white blood cells from AD patients (Feldhaus et al., 2011; Lunnon et al., 2012, 2013; Mecocci et al.,…”
Background
Mitochondrial Dysfunction in Aging and Alzheimer's Disease: Strategies to Protect Neurons
Reddy, P. H. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1754 · Cited by 188
“Oxidative damage has been reported in aging and age-related neurodegenerative diseases, including AD (6, 22, 32, 45, 55, 58, 64, 81).”

Authors: Parker, W. D., Filley, C. M., & Parks, J. K.
Affiliations: University of Colorado Denver (US)
ORCID: Filley, Christopher M.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1990-08
Volume: 40
Issue: 8
Pages: 1302-1302
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.40.8.1302
OpenAlex: W1988731658
Cited by: 598
References: 0
Citations by year: 2026: 19 · 2025: 10 · 2024: 12 · 2023: 20 · 2022: 9 · 2021: 22 · 2020: 25 · 2019: 19 · 2018: 18 · 2017: 18 · 2016: 28 · 2015: 10 · 2014: 10 · 2013: 21 · 2012: 15
FWCI: 7.27
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (7r01ns025382-06)
National Institute of Neurological Disorders and Stroke (NS25382)
National Center for Research Resources (RR-69)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cytochrome oxidase deficiency, Alzheimer's disease, platelet mitochondria, electron transport chain, mitochondrial dysfunction, systemic disease
MeSH terms: Aged, Alzheimer Disease, Blood Platelets, Electron Transport Complex IV, Electron Transport, Female, Humans, Kinetics, Male, Mitochondria, Reference Values, Cytochrome-c Oxidase Deficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cytochrome oxidase deficiency in Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks